MTNR1B
Melatonin receptor type 1B
As of the edition of 20 October 2026, MTNR1B (melatonin receptor type 1B, UniProt P49286) has 7 drugs tested at it and 9 companies on the list, 1 on route A and 3 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P49286
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 5
- Disease areas
- Mental health; Nervous system; Heart and blood vessels; Lungs and airways; Occupational diseases; Cancer; Urinary and reproductive; Pregnancy and women's health
- Registered trials of its drugs
- 421
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 4 |
| Went quiet | 2 |
| Stopped | 1 |
| Total | 7 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Melatonin | Marketed | Phase 4 | none listed |
| Ramelteon | Marketed | Phase 4 | none listed |
| Tasimelteon | Marketed | Phase 4 | Ends 2035 |
| Agomelatine | Marketed | Phase 4 | none listed |
| Piromelatine | Stopped | Phase 3 | none listed |
| KI1001 | Went quiet | Phase 3 | none listed |
| AGO178C | Went quiet | Phase 1 | none listed |
7 of 7 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 3 |
| Undetermined | 5 |
| Total on the list | 9 |
| Company | Route |
|---|---|
| Vanda Pharmaceuticals | Route B |
| Takeda | Route B |
| Nobelpharma | Route B |
The other 6 companies at MTNR1B
In the product9 companies in all; 6 are not named here, and no score is.
See the 9 companies at MTNR1B, ranked, with the facts behind eachRequest access. Nothing is shown until you do.